Inflammatory Markers and Cognitive Performance in Patients With Schizophrenia Treated With Lurasidone

被引：0
作者：
Miller, Brian [1 ]
Pikalov, Andrei [1 ]
Siu, Cynthia [1 ]
Tocco, Michael [1 ]
Tsai, Joyce [1 ]
Harvey, Philip [1 ]
Loebel, Antony [1 ]
机构：
[1] Sunov Pharmaceut Inc, Ft Lee, NJ USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2017年 / 42卷
关键词：
Inflammatory Markers; Cognitive Functioning; Lurasidone; Lipids; Schizophrenia; Functional Capacity; Antipsychotic Treatment;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
W172
引用
收藏
页码：S585 / S585
页数：1
相关论文
共 50 条
  • [21] Significant Weight Gain With the Administration of Lurasidone and Valproic Acid in Schizophrenia and Bipolar Disorder Patients
    Okura, Shohei
    Deguchi, Yasuhiko
    Cho, Tetsuji
    Kageyama, Yuki
    Inoue, Koki
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (11)
  • [22] Negative mood states as a correlate of cognitive performance and self-assessment of cognitive performance in bipolar disorder versus schizophrenia
    Dalkner, Nina
    Moore, Raeanne C.
    Depp, Colin A.
    Ackerman, Robert A.
    Pinkhame, Amy E.
    Harvey, Philip D.
    SCHIZOPHRENIA RESEARCH, 2023, 252 : 1 - 9
  • [23] Serum inflammatory markers and their associations with white matter integrity of the corpus callosum in schizophrenia patients and healthy controls
    Michalczyk, Anna
    Tyburski, Ernest
    Podwalski, Piotr
    Waszczuk, Katarzyna
    Rudkowski, Krzysztof
    Kucharska-Mazur, Jolanta
    Mak, Monika
    Rek-Owodzin, Katarzyna
    Plichta, Piotr
    Bielecki, Maksymilian
    Andrusewicz, Wojciech
    Cecerska-Heryc, Elzbieta
    Samochowiec, Agnieszka
    Misiak, Blazej
    Sagan, Leszek
    Samochowiec, Jerzy
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2022, 116
  • [24] Association Between Inflammatory Markers and Negative Symptoms in Individuals With Persistent Symptoms of Schizophrenia Treated With Clozapine
    Goldsmith, David
    Kopelovich, Sarah
    Novacek, Derek
    Widener, Jonathon
    Wommack, Evanthia
    Felger, Jennifer
    Miller, Andrew
    Cotes, Robert
    NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S390 - S391
  • [25] Prefrontal cognitive deficits in patients with schizophrenia treated with atypical or conventional antipsychotics
    Müller, U
    Werheid, K
    Hammerstein, E
    Jungmann, S
    Becker, T
    EUROPEAN PSYCHIATRY, 2005, 20 (01) : 70 - 73
  • [26] Effect of Aripiprazole on Cognitive Function and Hyperprolactinemia in Patients with Schizophrenia Treated with Risperidone
    Lee, Bong Ju
    Lee, Seung Ju
    Kim, Min Kyung
    Lee, Jung Goo
    Park, Sung Woo
    Kim, Gyung Mee
    Kim, Young Hoon
    CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2013, 11 (02) : 60 - 66
  • [27] Is Quality of Life Related to Cognitive Performance or Negative Symptoms in Patients with Schizophrenia? Results from a Double-blind, Active-controlled, Lurasidone Extension Study
    Harvey, Philip D.
    Loebel, Antony
    Cucchiaro, Josephine
    Phillips, Debra
    Siu, Cynthia
    NEUROPSYCHOPHARMACOLOGY, 2013, 38 : S515 - S515
  • [28] D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder
    Potkin, Steven G.
    Keator, David B.
    Kesler-West, Marilyn L.
    Nguyen, Dana D.
    van Erp, Theo G. M.
    Mukherjee, Jogeshwar
    Shah, Nikunj
    Preda, Adrian
    CNS SPECTRUMS, 2014, 19 (02) : 176 - 181
  • [29] Effect of lurasidone on neurocognitive performance in patients with schizophrenia: A short-term placebo- and active-controlled study followed by a 6-month double-blind extension
    Harvey, Philip D.
    Siu, Cynthia O.
    Hsu, Jay
    Cucchiaro, Josephine
    Maruff, Paul
    Loebel, Antony
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 (11) : 1373 - 1382
  • [30] Relationships Between Inflammatory Markers and Kynurenine Metabolites in Patients With Schizophrenia but Not Healthy Controls
    Goldsmith, David
    Massa, Nicholas
    Pearce, Bradley
    Wommack, Evanthia
    Alrohaibani, Alaaeddin
    Goel, Neha
    Cuthbert, Bruce
    Fargotstein, Molly
    Barr, Dana Boyd
    Panuwet, Parinya
    Miller, Andrew
    Duncan, Erica
    BIOLOGICAL PSYCHIATRY, 2019, 85 (10) : S365 - S365
12345